Title:Anti-EGFR Binding Nanobody Delivery System to Improve the Diagnosis and Treatment of Solid Tumours
VOLUME: 15 ISSUE: 3
Author(s):Long Wang, Gengyuan Zhang, Long Qin, Huili Ye, Yan Wang, Bo Long and Zuoyi Jiao*
Affiliation:The First Department of General Surgery, Lanzhou University Second Hospital, Lanzhou 730000, Gansu Province, The First Department of General Surgery, Lanzhou University Second Hospital, Lanzhou 730000, Gansu Province, The Cuiying Center, Lanzhou University Second Hospital, Lanzhou 730000, Gansu, The Cuiying Center, Lanzhou University Second Hospital, Lanzhou 730000, Gansu, The Cuiying Center, Lanzhou University Second Hospital, Lanzhou 730000, Gansu, The First Department of General Surgery, Lanzhou University Second Hospital, Lanzhou 730000, Gansu Province, The First Department of General Surgery, Lanzhou University Second Hospital, Lanzhou 730000, Gansu Province
Keywords:Diagnosis and treatment, EGFR, molecular structure, nanobody, patent, solid tumor.
Abstract:
Background: Epidermal Growth Factor Receptor (EGFR) and members of its homologous
protein family mediate transmembrane signal transduction by binding to a specific ligand,
which leads to regulated cell growth, differentiation, proliferation and metastasis. With the development
and application of Genetically Engineered Antibodies (GEAs), Nanobodies (Nbs) constitute a
new research hot spot in many diseases. A Nb is characterized by its low molecular weight, deep
tissue penetration, good solubility and high antigen-binding affinity, the anti-EGFR Nbs are of significance
for the diagnosis and treatment of EGFR-positive tumours.
Objective: This review aims to provide a comprehensive overview of the information about the
molecular structure of EGFR and its transmembrane signal transduction mechanism, and discuss
the anti-EGFR-Nbs influence on the diagnosis and treatment of solid tumours.
Methods: Data were obtained from PubMed, Embase and Web of Science. All patents are searched
from the following websites: the World Intellectual Property Organization (WIPO®), the United
States Patent Trademark Office (USPTO®) and Google Patents.
Results: EGFR is a key target for regulating transmembrane signaling. The anti-EGFR-Nbs for targeted
drugs could effectively improve the diagnosis and treatment of solid tumours.
Conclusion: EGFR plays a role in transmembrane signal transduction. The Nbs, especially anti-
EGFR-Nbs, have shown effectiveness in the diagnosis and treatment of solid tumours. How to increase
the affinity of Nb and reduce its immunogenicity remain a great challenge.
